Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab

Clinical Colorectal Cancer

Volumn 6, Issue 3, 2006, Pages 202-207

  Yoo, Peter S ^a   Lopez Soler, Reynold I ^a   Longo, Walter E ^a   Cha, Charles H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiangiogenesis; Carcinoma; Hepatectomy; Vascular endothelial growth factor

Indexed keywords

ALCOHOL; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PLACEBO; VASCULOTROPIN;

ANTIGEN DETECTION; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CRYOTHERAPY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG HALF LIFE; GOLD STANDARD; HUMAN; LIVER METASTASIS; LIVER REGENERATION; LIVER RESECTION; NONHUMAN; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SURGICAL APPROACH; SURGICAL MORTALITY; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; UNITED STATES; WOUND HEALING IMPAIRMENT;

EID: 33750180077     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.036     Document Type: Review

References (67)

1. American Cancer Society [Web site]. How many people get colorectal cancer? Available at: www.cancer.org. Accessed June 6, 2006.
2. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49:8-31.
3. Younes RN, Rogatko A, Brennan MF. The influence of intraoperative hypotension and perioperative blood transfusion on disease-free survival in patients with complete resection of colorectal liver metastases. Ann Surg 1991; 214:107-113.
4. Hughes K, Scheele J, Sugarbaker PH. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North Am 1989; 69:339-359.
5. Fortner JG. Recurrence of colorectal cancer after hepatic resection. Am J Surg 1988; 155:378-382.
6. Cady B, Jenkins RL, Steele GD Jr, et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998; 227:566-571.
7. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15:938-946.
8. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for Improving resectability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23:7125-7134.
9. Jaeck D, Bachellier P, Guiguet M, et al. Long-term survival following resection of colorectal hepatic metastases. Association Francaise de Chirurgie. Br J Surg 1997; 84:977-980.
10. Scheele J, Stang R, Altendorf-Hofmann A, et al. Resection of colorectal liver metastases. World J Surg 1995; 19:59-71.
11. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14:13-16.
12. Scheele J, Stangl R, Altendorfhofmann A. Hepatic metastases from colorectal-carcinoma - impact of surgical resection on the natural-history. Br J Surg 1990; 77:1241-1246.
13. DeMatteo RP, Palese C, Jarnagin WR, et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 2000; 4:178-184.
14. Nordlinger B. Résection chirurgicale des metastases hépatiques. Traitement des Metastases Hepatiques dons Cancers Colorectaux. Paris, France: Springer Verlag; 1992:141-159.
15. Belghiti J, Hiramatsu K, Benoist S, et al. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191:38-46.
16. Jarnagin WR, Gonen M, Fong Y, et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 2002; 236:397-406; discussion 406-407.
17. Abdalla EK, Noun R, Belghiti J. Hepatic vascular occlusion: which technique? Surg Clin North Am 2004; 84:563-585.
18. Makuuchi M, Mori T, Gunven P, et al. Safety of hemihepatic vascular occlusion during resection of the liver. Surg Gynecol Obstet 1987; 164:155-158.
19. Clavien PA, Selzner M, Rudiger HA, et al. A prospective randomized study in 100 consecutive patients undergoing major liver resection with versus without ischemic preconditioning. Ann Surg 2003; 238:843-850; discussion 851-852.
20. Huguet C, Gavelli A. Total vascular exclusion for liver resection. Hepatogastroenterology 1998; 45:368-369.
21. Makuuchi M, Hasegawa H, Yamazaki S. Intraoperative ultrasonic examination for hepatectomy. Ultrasound Med Biol 1983; Suppl 2:493-497.
22. Makuuchi M, Hasegawa H, Yamazaki S. Development on segmentectomy and subsegmentectomy of the liver due to introduction of ultrasonography. Nippon Geka Gakkai Zasshi 1983; 84:913-917.
23. Bismuth H, Castaing D, Garden OJ. The use of operative ultrasound in surgery of primary liver tumors. World J Surg 1987; 11:610-614.
24. Jarnagin WR, Bach AM, Winston CB, et al. What is the yield of intraoperative ultrasonography during partial hepatectomy for malignant disease? J Am Coll Surg 2001; 192:577-583.
25. Solomon MJ, Stephen MS, Gallinger S, et al. Does intraoperative hepatic ultrasonography change surgical decision making during liver resection? Am J Surg 1994; 168:307-310.
26. Cha C, Lee FT Jr, Rikkers LF, et al. Rationale for the combination of cryoablation with surgical resection of hepatic tumors. J Gastrointest Surg 2001; 5:206-213.
27. Jansen MC, van Duijnhoven FH, van Hillegersberg R, et al. Adverse effects of radiofrequency ablation of liver tumours in the Netherlands. Br J Surg 2005; 92:1248-1254.
28. Sutherland LM, Williams JA, Padbury RT, et al. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006; 141:181-190.
29. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg 2000; 231:480-486.
30. de Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolos plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997; 15:808-815.
31. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer. J Clin Oncol 1998; 16:301-308.
32. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-2048.
33. Lorenz M, Hochmuth K, Muller HH. Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer. N Engl J Med 2000; 342:1525-1526; author reply 1526-1527.
34. Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992; 10:1112-1118.
35. Armand JP, Ducreux M, Mahjoubi M, et al. CPT-11 (irinotecan) in the treatment of colorectal cancer. Eur J Cancer 1995; 31A:1283-1287.
36. Conti JA, Kemeny NE, Salts LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709-715.
37. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-260.
38. Parikh AA, Gentner B, Wu TT, et al. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 2003; 7:1082-1088.
39. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-2072.
40. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-353.
41. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15:460-466.
42. Bilchik AJ, Poston G, Curley SA, et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 2005; 23:9073-9078.
43. Nordlinger B, Brouquet A, Penna C, et al. Complete radiological response of colorectal liver metastases (LM) after chemotherapy: does it mean cure? J Clin Oncol 2006; 24(18 suppl):146s (Abstract #3501).
44. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
45. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005; 91:173-180.
46. Howdieshell TR, Callaway D, Webb WL, et al. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001; 96:173-182.
47. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res 2002; 105:43-47.
48. Michalopoulos GK, DeFrances MC. Liver regeneration. Science 1997; 276:60-66.
49. DeAngelis RA, Kovalovich K, Cressman DE, et al. Normal liver regeneration in p50/nuclear factor kappaB1 knockout mice. Hepatology 2001; 33:915-924.
50. Li DQ, Lokeshwar BL, Solomon A, et al. Regulation of MMP-9 production by human corneal epithelial cells. Exp Eye Res 2001; 73:449-459.
51. Mochida S, Ishikawa K, Inao M, et al. Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and KDR/flk-1, in regenerating rat liver. Biochem Biophys Res Commun 1996; 226:176-179.
52. Taniguchi E, Sakisaka S, Matsuo K, et al. Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem 2001; 49:121-130.
53. Akiyoshi F, Sata M, Suzuki H, et al. Serum vascular endothelial growth factor levels in various liver diseases. Dig Dis Sci 1998; 43:41-45.
54. Drixler TA, Vogten MJ, Ritchie ED, et al. Liver regeneration is an angiogenesis- associated phenomenon. Ann Surg 2002; 236:703-711; discussion 711-712.
55. Vogten JM, Drixler TA, te Velde EA, et al. Angiostatin inhibits experimental liver fibrosis in mice. Int J Colorectal Dis 2004; 19:387-394.
56. Makino H, Shimizu H, Ito H, et al. Changes in growth factor and cytokine expression in biliary obstructed rat liver and their relationship with delayed liver regeneration after partial hepatectomy. World J Gastroenterol 2006; 12:2053-2059.
57. Namisaki T, Yoshiji H, Kojima H, et al. Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats. J Hepatol 2006; 44:568-575.
58. Assy N, Spira G, Paizi M, et al. Effect of vascular endothelial growth factor on hepatic regenerative activity following partial hepatectomy in rats. J Hepatol 1999; 30:911-915.
59. Redaelli CA, Semela D, Carrick FE, et al. Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 2004; 40:305-312.
60. LeCouter J, Moritz DR, Li B, et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003; 299:890-893.
61. Sturm J, Keese M, Zhang H, et al. Liver regeneration in FGF-2-deficient mice: VEGF acts as potential functional substitute for FGF-2. Liver Int 2004; 24:161-168.
62. Yoon SS, Kim SH, Gonen M, et al. Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 2006; 13:353-362.
63. Gruenberger BSW, Tamandl D, Puhalla H, et al. Neoadjuvant chemotherapy including bevacizumab in potentially curable metastatic colorectal cancer. J Clin Oncol 2006; 24:3546.
64. Michael M, Vancustem E, Kretzschmar A, et al. Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - preliminary results from the First Beat-study. J Clin Oncol 2006; 24:3523.
65. Gruenberger T, Gruenberger B, Scheithauer W. Neoadjuvant therapy with bevacizumab. J Clin Oncol 2006; 24:2592-2593; author reply 2593-2594.
66. Ellis LM, Curley SA, Grothey A. Surgical resection after downsizing of colorectal liver metastasis in the era of bevacizumab. J Clin Oncol 2005; 23:4853-4855.
67. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19:843-850.